Dr. Michael Miller is responsible for regulatory strategy, regulatory CMC, and regulatory operations. He brings more than 25 years of regulatory and product development experience in infectious disease and oncology, during which time he has contributed to the discovery and/or development of six marketed antiviral and oncology drugs.

Before joining AlloVir, Dr. Miller served as Vice President and Head of Regulatory Affairs at Idera Pharmaceuticals. He spent 23 years at Merck before Idera, holding various roles of increasing responsibility that culminated as Executive Director, Oncology Regulatory Affairs.

While working in antiviral drug discovery at Merck, Dr. Miller and his team advanced more than two dozen anti-HIV and anti-HCV compounds into clinical development, ultimately leading to marketing approvals for four drugs, including a first-in-class HIV integrase inhibitor. He then moved to Oncology Regulatory Affairs at Merck to support early- and late-stage clinical development of immuno-oncology products. In that role, Dr. Miller led marketing application submissions to expand the oncology indications for Merck’s PD-1 inhibitor.

Dr. Miller solidified his focus on infectious disease through a postdoctoral fellowship studying the HIV integrase enzyme at The Salk Institute for Biological Studies. He is a co-author of more than 100 peer-reviewed scientific publications.

Dr. Miller holds a PhD in Immunology from Harvard University and a BA in Microbiology from the University of Kansas.